Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for serologic testing for Acquired Immunodeficiency Syndrome (AIDS), with an effective date of May 15, 2026. Here's what billing teams need to know before that date.
CMS serologic AIDS testing coverage policy has been on the books for decades, but this 2026 modification signals that CMS is revisiting how it covers — and pays for — HIV/AIDS-related diagnostic testing under Medicare. The policy does not carry a numbered policy code in this revision. Importantly, the updated policy document does not list specific CPT or HCPCS codes, so your billing team should pull the full policy text directly from CMS before May 15, 2026, to confirm which codes fall under this coverage policy.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Serologic Testing for Acquired Immunodeficiency Syndrome (AIDS) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Infectious disease, internal medicine, primary care, laboratory/pathology, public health clinics |
| Key Action | Pull the full policy text from CMS before May 15, 2026, confirm which serologic testing codes your practice bills, and audit pending claims for alignment with the updated criteria |
CMS AIDS Serologic Testing Coverage Criteria and Medical Necessity Requirements 2026
The CMS AIDS serologic testing coverage policy governs Medicare reimbursement for blood-based tests that detect HIV antibodies, antigens, or viral markers used in the diagnosis and monitoring of HIV/AIDS. This category of testing has historically been covered when a treating physician establishes medical necessity — meaning the patient's clinical presentation, risk factors, or ongoing disease management justify the test.
CMS requires that serologic testing for AIDS meet medical necessity standards tied to the clinical context. A test ordered without documented clinical indication — no relevant symptoms, no documented risk exposure, no ongoing HIV management — is a claim denial waiting to happen. That documentation gap is where most billing problems originate.
Under the updated policy, the medical necessity determination rests on whether the treating provider has documented a valid clinical reason for the test in the patient's record. CMS does not cover serologic testing ordered purely for screening in the general Medicare population under this specific policy — that's a separate benefit category. If your physicians are ordering these tests as part of HIV management or diagnostic workup, the clinical indication needs to be explicit in the order and the progress note.
Prior authorization is not typically required for routine serologic AIDS testing under Medicare fee-for-service. But if your practice bills through a Medicare Advantage plan, check that plan's specific prior authorization requirements — Medicare Advantage plans can and do impose prior auth requirements that traditional Medicare does not.
The coverage policy also intersects with local coverage determinations issued by Medicare Administrative Contractors. Your MAC may have issued an LCD that adds coverage criteria or code-specific guidance on top of this national policy. Check your MAC's website for any active LCD addressing HIV serologic testing in your jurisdiction before May 15, 2026.
CMS AIDS Serologic Testing Exclusions and Non-Covered Indications
CMS does not cover serologic AIDS testing when it is ordered without a documented clinical indication. Routine screening of the general Medicare population — absent a specific risk factor or clinical reason — does not meet medical necessity under this coverage policy.
Testing ordered as a blanket panel without individual medical justification is also at risk. If your lab or ordering provider includes HIV serology as part of a broad, undifferentiated test battery without noting why this specific patient needs this specific test, expect scrutiny on those claims.
Duplicate testing — ordering the same serologic test multiple times within a short period without documented clinical reason for repeat testing — is another non-coverage trigger. CMS expects that repeat testing reflects a genuine clinical need, such as monitoring treatment response or confirming a prior result.
Coverage Indications at a Glance
Because the updated policy document does not list specific covered indications with code-level detail, the table below reflects the general coverage framework for CMS AIDS serologic testing based on the policy title and standard Medicare coverage principles. Confirm specifics against the full policy text before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Diagnostic workup for suspected HIV/AIDS with documented clinical indication | Covered | Not listed in policy document | Medical necessity documentation required in patient record |
| Monitoring of known HIV/AIDS patients under active treatment | Covered | Not listed in policy document | Clinical rationale for each test episode must be documented |
| Serologic testing ordered without documented clinical indication | Not Covered | Not listed in policy document | Claim denial risk; auditors look for missing documentation |
| General population screening without specific risk documentation | Not Covered | Not listed in policy document | Separate Medicare screening benefit may apply — do not bill under this policy |
| Duplicate serologic testing without clinical justification for repeat | Not Covered | Not listed in policy document | Frequency edits may apply at the MAC level |
CMS AIDS Serologic Testing Billing Guidelines and Action Items 2026
Here's what your billing team and revenue cycle staff should do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the full policy text now. The source document is available at the CMS policy record. The policy data available at the time of this post does not include specific CPT or HCPCS codes. Do not assume your current charge capture is aligned — verify it directly against the updated policy language before the effective date. |
| 2 | Audit your ordering providers' documentation habits. Serologic AIDS testing billing lives or dies on the clinical note. Check that your physicians, NPs, and PAs are documenting the specific clinical indication for every HIV serology order. "Routine labs" does not cut it for medical necessity under this policy. |
| 3 | Check your MAC's active LCDs. Your Medicare Administrative Contractor may have a local coverage determination that adds code-specific or frequency-specific criteria on top of this national policy. Go to the CMS LCD search tool, enter your MAC, and search for HIV or AIDS testing LCDs. If one exists, your billing guidelines need to reflect both the national policy and the LCD. |
| 4 | Review your Medicare Advantage contracts separately. Prior authorization requirements for serologic AIDS testing vary by MA plan. Traditional Medicare fee-for-service generally does not require prior auth for this testing, but your MA payers may. Pull each MA plan's policy before May 15, 2026, and confirm whether prior auth is required. |
| 5 | Flag any pending claims for review. If you have claims in flight for serologic AIDS testing that were billed under criteria that may shift with this modification, hold them for review until you've confirmed the updated policy language. A denied claim is recoverable. A fraudulent billing pattern is not. |
| 6 | Talk to your compliance officer if the documentation picture at your practice is unclear. This is not a high-complexity policy change on its face, but if your practice has significant volume in HIV/AIDS testing — infectious disease groups, federally qualified health centers, HIV specialty clinics — the financial exposure is real. Get your compliance officer involved in the documentation review before May 15, 2026. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for AIDS Serologic Testing Under This Policy
The updated CMS policy document for Serologic Testing for Acquired Immunodeficiency Syndrome (AIDS) does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for a high-level CMS national policy — the code-level specifics often live in MAC-issued LCDs or CMS billing instructions rather than the policy document itself.
Do not bill based on assumed codes. Your billing team should:
- Review the full CMS policy text at app.payerpolicy.org/p/cms/265-v1. for any code references in the body of the document
- Check your MAC's LCD for HIV/AIDS serologic testing, which will list covered CPT codes and applicable ICD-10 diagnosis codes
- Cross-reference your current charge master entries for HIV antibody testing, Western blot, HIV RNA quantification, and related serologic tests against the MAC LCD criteria
Common serologic testing in this clinical area — HIV antibody tests, combination antigen/antibody tests, confirmatory assays — does have associated CPT codes that your MAC LCD will address. But because this policy does not list them, we will not assign codes here. Guessing codes in a compliance context is how billing errors become billing violations.
If your MAC has not issued an LCD for this testing category, contact your MAC's provider outreach and education team directly. They can tell you which codes are covered under the national policy in your jurisdiction.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.